SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about completion of US FDA inspection

26 Jul 2023 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Koltur Village, Shameerpet, Medchal District, Telangana, from 17th July to 26thth July 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1531.50 7.60 (0.50%)
24-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1941.00
Dr. Reddys Labs. 1152.60
Cipla 1410.90
Lupin 2369.45
Zydus Lifesciences 1108.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: